Global Chronic Lymphocytic Leukemia Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 216 pages | ID: GA21F6EB001EN
Precision Business Insights (PBI)

Abstracts

Global Chronic Lymphocytic Leukemia Treatment Market:

Global chronic lymphocytic leukemia treatment market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for chronic lymphocytic leukemia treatment is projected to reach US$ XX Mn by 2023.

Chronic lymphocytic leukemia or β-cell chronic lymphocytic leukemia, which is the common type of leukemia of the WBC in adults. β-cell lymphocytes are a type of white blood cells, which produce in the bone marrow, develop in lymph nodes. These cells produce antibodies which fight against infection. In chronic lymphocytic leukemia, β-cells produce in an uncontrolled manner and accumulate in blood and bone marrow, and they crowd out healthy blood cells. Majorly, chronic lymphocytic leukemia occurs in adults, however, sometimes it occurs in the teenagers and children. Chronic lymphocytic leukemia is diagnosed by using complete blood count test, flow cytometry test, gene tests, and bone marrow tests.

The global market for chronic lymphocytic leukemia treatment is expected to grow at a significant CAGR due to increase in the prevalence of chronic lymphocytic leukemia. According to WHO chronic lymphocytic leukemia is more prominent in the developed world such as North America and Europe due to genetic factors. The global incidence of chronic lymphocytic leukemia was 94,960 in 2008 with the developing countries, which is increased to 123,379 in 2010 and predicted to reach 282,683 new cases for 2020. Increase in aging population, excessive exposure to carcinogenic chemicals, and genetical blood disorders are the major drivers for the growth of chronic lymphocytic leukemia treatment market. Furthermore, growing disease awareness, and rising incidences of comorbidities may accelerates the growth of the market. Increased research and development in oncology sector, introduction of novel therapies, promising pipeline products, and new innovation in drug development helps in the growth of chronic lymphocytic leukemia treatment market. However, the high cost of the treatment for chronic lymphocytic leukemia and stringent regulatory policies might hamper the growth of chronic lymphocytic leukemia treatment market over the forecast period.

Chronic lymphocytic leukemia treatment market has been segmented based on the drug type, route of administration, cancer type, and distribution channel

Based on the drug type, chronic lymphocytic leukemia treatment market has been segmented into the following:

• Targeted drug
• Purine analogues
• Alkylating agents
• Corticosteroids
• Other drugs
• Chemotherapy

Based on the cancer type, chronic lymphocytic leukemia treatment market has been segmented into the following:

• B-cell chronic lymphocytic leukemia
• T-cell chronic lymphocytic leukemia
• Natural killer chronic lymphocytic leukemia

Based on the route of administration, chronic lymphocytic leukemia treatment market has been segmented into the following:

• Parenteral
• Oral
• Others

Based on distribution channel, chronic lymphocytic leukemia treatment market has been segmented into the following:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The global chronic lymphocytic leukaemia treatment market is in developing stage in nature with several international players operating in the chronic lymphocytic leukemia treatment. Conventionally, chemo drugs are dominating the chronic lymphocytic leukemia treatment market. For instance, Rituximab, Imbruvica, and Idelalisib are the chemo drugs used in the treatment of chronic lymphocytic leukemia patients in combination or alone. Efficacy of these drugs in chronic lymphocytic leukemia is potentially replaced chemoimmunotherapy. Co-development and collaboration agreements are some of the key strategies adopted by some market players. For instance, GlaxoSmithKline plc and Genmab A/S, have entered into co-development and collaboration agreement for drug Arzerra (ofatumumab), used in the treatment of chronic lymphocytic leukemia. Similarly, venetoclax by Roche, in collaboration with AbbVie, received approval from the US FDA for the treatment of chronic lymphocytic leukemia. With an increasing number of drug approvals, the chronic lymphocytic leukemia treatment market is anticipated to post a positive outlook over the forecast period.

Geographically, the chronic lymphocytic leukemia treatment market has been segmented into following regions Viz. North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. According to American Cancer Society, approximately 15,000 new cases has been observed every year for chronic lymphocytic leukaemia in the country. Chronic lymphocytic leukemia is more prominent in the developed countries like North America and Europe owing to unhealthy lifestyle and genetic factors. Increasing investment in research and development by drug developing firms, improving healthcare infrastructure in India, and China promoting the growth of chronic lymphocytic leukemia treatment market in Asia-Pacific region.

Some of the players in chronic lymphocytic leukemia treatment are Genzyme Corporation (U.S.), Ono pharmaceuticals Co. Ltd. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (U.S.), Arno Therapeutics Inc. (U.S.), Infinity Pharmaceuticals (U.S.), Innate Pharma SA (France), AstraZeneca (U.K.), Bellicum Pharmaceuticals Inc. (U.S.), GlaxoSmithKline Plc (U.K.), and Novartis AG (Switzerland) to name a few.

In April 2016, U.S. Food and Drug Administration approved the venetoclax for the treatment of chronic lymphocytic leukemia treatment with 17p chromosome deletion

In 2014, Genentech launched the GA101/RG7159 for the chronic lymphocytic leukemia treatment

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET INTRODUCTION

2.1. Global Chronic Lymphocytic Leukemia Treatment Market– Taxonomy
2.2. Global Chronic Lymphocytic Leukemia Treatment Market–Definitions
  2.2.1. Drug Type
  2.2.2. Cancer Type

3. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Chronic Lymphocytic Leukemia Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Chronic Lymphocytic Leukemia Treatment Market– Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Chronic Lymphocytic Leukemia Treatment Market– Recent Product Launches

4. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Targeted Drugs
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Purine Analogues
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Alkylating Agents
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Corticosteroids
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Others
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis

6. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET FORECAST, BY CANCER TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. B-cell Chronic Lymphocytic Leukemia
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. T-cell Chronic Lymphocytic Leukemia
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Natural Killer Chronic Lymphocytic Leukemia
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Targeted Drugs
    9.1.1.2. Purine Analogues
    9.1.1.3. Alkylating Agents
    9.1.1.4. Corticosteroids
    9.1.1.5. Other Drugs
  9.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. B-cell Chronic Lymphocytic Leukemia
    9.1.2.2. T-cell Chronic Lymphocytic Leukemia
    9.1.2.3. Natural Killer Chronic Lymphocytic Leukemia
  9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Hospital Pharmacies
    9.1.3.2. Retail Pharmacies
    9.1.3.3. Online Pharmacies
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
  9.1.6. North America Chronic Lymphocytic Leukemia Treatment Market Dynamics – Trends

10. EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Targeted Drugs
    10.1.1.2. Purine Analogues
    10.1.1.3. Alkylating Agents
    10.1.1.4. Corticosteroids
    10.1.1.5. Other Drugs
  10.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. B-cell Chronic Lymphocytic Leukemia
    10.1.2.2. T-cell Chronic Lymphocytic Leukemia
    10.1.2.3. Natural Killer Chronic Lymphocytic Leukemia
  10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Hospital Pharmacies
    10.1.3.2. Retail Pharmacies
    10.1.3.3. Online Pharmacies
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
  10.1.6. Europe Chronic Lymphocytic Leukemia Treatment Market Dynamics – Trends

11. ASIA-PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Targeted Drugs
    11.1.1.2. Purine Analogues
    11.1.1.3. Alkylating Agents
    11.1.1.4. Corticosteroids
    11.1.1.5. Other Drugs
  11.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. B-cell Chronic Lymphocytic Leukemia
    11.1.2.2. T-cell Chronic Lymphocytic Leukemia
    11.1.2.3. Natural Killer Chronic Lymphocytic Leukemia
  11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Hospital Pharmacies
    11.1.3.2. Retail Pharmacies
    11.1.3.3. Online Pharmacies
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
  11.1.6. Asia-Pacific Chronic Lymphocytic Leukemia Treatment Market Dynamics – Trends

12. LATIN AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Targeted Drugs
    12.1.1.2. Purine Analogues
    12.1.1.3. Alkylating Agents
    12.1.1.4. Corticosteroids
    12.1.1.5. Other Drugs
  12.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. B-cell Chronic Lymphocytic Leukemia
    12.1.2.2. T-cell Chronic Lymphocytic Leukemia
    12.1.2.3. Natural Killer Chronic Lymphocytic Leukemia
  12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Hospital Pharmacies
    12.1.3.2. Retail Pharmacies
    12.1.3.3. Online Pharmacies
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
  12.1.6. Latin America Chronic Lymphocytic Leukemia Treatment Market Dynamics – Trends

13. MIDDLE EAST & AFRICA CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Targeted Drugs
    13.1.1.2. Purine Analogues
    13.1.1.3. Alkylating Agents
    13.1.1.4. Corticosteroids
    13.1.1.5. Other Drugs
  13.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. B-cell Chronic Lymphocytic Leukemia
    13.1.2.2. T-cell Chronic Lymphocytic Leukemia
    13.1.2.3. Natural Killer Chronic Lymphocytic Leukemia
  13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Hospital Pharmacies
    13.1.3.2. Retail Pharmacies
    13.1.3.3. Online Pharmacies
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
  13.1.6. MEA Chronic Lymphocytic Leukemia Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Genzyme Corporation (U.S.)
  14.2.2. Ono pharmaceuticals Co. Ltd. (Japan)
  14.2.3. F. Hoffmann-La Roche Ltd. (Switzerland)
  14.2.4. AbbVie Inc. (U.S.)
  14.2.5. Arno Therapeutics Inc. (U.S.)
  14.2.6. Infinity Pharmaceuticals (U.S.)
  14.2.7. Innate Pharma SA (France)
  14.2.8. AstraZeneca (U.K.)
  14.2.9. Bellicum Pharmaceuticals Inc. (U.S.)
  14.2.10. GlaxoSmithKline Plc (U.K.)
  14.2.11. Novartis AG (Switzerland)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS